Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer.
Curr Opin Obstet Gynecol. 2014.
PMID: 24335887
Review.
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2008 | 1 |
| 2014 | 1 |
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 0 |
Search Results
4 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer.
Kim M, Agarwal S, Tripathy D.
Kim M, et al.
Curr Opin Obstet Gynecol. 2014 Feb;26(1):27-33. doi: 10.1097/GCO.0000000000000043.
Curr Opin Obstet Gynecol. 2014.
PMID: 24335887
Review.
PURPOSE OF REVIEW: To review the most recent developments in the treatment of human epidermal growth factor receptor type 2 (HER2)-positive breast cancer with novel HER2-targeting agents and combinations that have sig …
PURPOSE OF REVIEW: To review the most recent developments in the treatment of human epidermal growth factor …
Item in Clipboard
Human epidermal growth factor receptor 2-positive digestive tumors.
Wagner AD, Özdemir BC, Rüschoff J.
Wagner AD, et al.
Curr Opin Oncol. 2019 Jul;31(4):354-361. doi: 10.1097/CCO.0000000000000544.
Curr Opin Oncol. 2019.
PMID: 31170116
Review.
PURPOSE OF REVIEW: This manuscript aims at providing an update and overview on the role of Human epidermal growth factor receptor 2 (HER2) testing and HER2-directed therapies in digestive tumors. ...Various HER2-targeting therapies, which …
PURPOSE OF REVIEW: This manuscript aims at providing an update and overview on the role of Human epidermal growth …
Item in Clipboard
Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer.
Graff SL, Yan F, Abdou Y.
Graff SL, et al.
Clin Breast Cancer. 2023 Oct;23(7):e380-e393. doi: 10.1016/j.clbc.2023.05.003. Epub 2023 May 13.
Clin Breast Cancer. 2023.
PMID: 37407378
Free article.
Review.
Human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) is an aggressive tumor type, accounting for 15% to 20% of the approximately 300,000 new BC cases in the United States each year. ...Tar …
Human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) is …
Item in Clipboard
Factors predictive of response to hormone therapy in breast cancer.
Rastelli F, Crispino S.
Rastelli F, et al.
Tumori. 2008 May-Jun;94(3):370-83. doi: 10.1177/030089160809400314.
Tumori. 2008.
PMID: 18705406
Review.
CONCLUSIONS: Available clinical data are inconclusive to support preferential use of aromatase inhibitors over tamoxifen in progesterone-receptor-negative and HER-2-positive tumors, but it was also clear that lower estrogen receptors, lower progesteron …
CONCLUSIONS: Available clinical data are inconclusive to support preferential use of aromatase inhibitors over tamoxifen in progesterone- …
Item in Clipboard
Cite
Cite